Institute for Medicinal Plants Research "Dr. Josif Pančić", Tadeuša Košćuška 1, Belgrade, Serbia.
Department of Obstetrics and Gynecology, Division of Basic Sciences and Translational Medicine, University of Texas Medical Branch, Galveston, TX, 77555, USA.
Naunyn Schmiedebergs Arch Pharmacol. 2024 Feb;397(2):763-781. doi: 10.1007/s00210-023-02682-4. Epub 2023 Sep 1.
This review aims to provide an in-depth analysis of the pharmacological properties of mangiferin, focusing primarily on its bioavailability and mechanisms of action, and its potential therapeutic applications, especially in the context of chronic diseases. We conducted a comprehensive examination of in vitro and in vivo studies, as well as clinical trials involving mangiferin or plant extracts containing mangiferin. The primary source of mangiferin is Mangifera indica, but it's also found in other plant species from the families Anacardiaceae, Gentianaceae, and Iridaceae. Mangiferin has exhibited a myriad of therapeutic properties, presenting itself as a promising candidate for treating various chronic conditions including neurodegenerative disorders, cardiovascular diseases, renal and pulmonary diseases, diabetes, and obesity. Despite the promising results showcased in many in vitro studies and certain animal studies, the application of mangiferin has been limited due to its poor solubility, absorption, and overall bioavailability. Mangiferin offers significant therapeutic potential in treating a spectrum of chronic diseases, as evidenced by both in vitro and clinical trials. However, the challenges concerning its bioavailability necessitate further research, particularly in optimizing its delivery and absorption, to harness its full medicinal potential. This review serves as a comprehensive update on the health-promoting and therapeutic activities of mangiferin.
这篇综述旨在深入分析芒果苷的药理学特性,重点关注其生物利用度和作用机制,以及其在治疗慢性疾病方面的潜在应用。我们对涉及芒果苷或含有芒果苷的植物提取物的体外和体内研究以及临床试验进行了全面检查。芒果苷的主要来源是 Mangifera indica,但它也存在于来自漆树科、龙胆科和鸢尾科的其他植物物种中。芒果苷具有多种治疗特性,是治疗各种慢性疾病(包括神经退行性疾病、心血管疾病、肾脏和肺部疾病、糖尿病和肥胖症)的有前途的候选药物。尽管在许多体外研究和某些动物研究中显示出了有希望的结果,但由于其溶解度、吸收和整体生物利用度差,芒果苷的应用受到限制。芒果苷在治疗一系列慢性疾病方面具有显著的治疗潜力,这一点在体外和临床试验中都得到了证实。然而,其生物利用度方面的挑战需要进一步的研究,特别是在优化其输送和吸收方面,以充分发挥其药用潜力。这篇综述是对芒果苷的保健和治疗活性的全面更新。